A study presented at the American Society of Hematology’s annual meeting found that the use of GLP-1 receptor agonists in patients with type 2 diabetes is associated with a lower risk of venous thromboembolism (VTE). The study compared GLP-1 RA users to those using DPP-4 inhibitors and found that GLP-1 RA users had an 18% lower risk of VTE, with lower risks of pulmonary embolism and deep venous thrombosis. This suggests that GLP-1 RA use may reduce the risk of VTE, but further research is needed to understand the mechanisms and causality of this association.
Source link
GLP-1 RA use tied to lower rate of venous thromboembolism in diabetes
